February 7, 2017 at 9:00PM EST
This presentation will provide an update on how immunotherapy has rapidly integrated into standard 1st and 2nd-Line and beyond treatment settings.
January 26, 2017 at 9:00PM EST
In this live webinar Dr. Taofeek K. Owonikoko and Dr. Ramaswamy Govindan will discuss key abstracts, presentations, and developments reported in Vienna, Austria during the recent (December 4-7, 2016) 17th World Conference on Lung Cancer (WCLC).
December 20, 2016 at 9:00PM EST - Recording Available
Immunotherapy is now a standard option for treatment of patients with non-small cell lung cancer and has been shown to improve survival compared to chemotherapy in a subset of patients. This
November 16, 2016 at 9:00PM EST - Recording Available
Recent meetings of the European Society of Medical Oncology (October 7-11, 2016) and the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology (September 22-24, 2016) provided important updates and new information relative to the multidisciplinary management of patients with lung cancer.
November 15, 2016 at 9:00PM EST - Recording Available
A recent IASLC webinar (July 27, 2016 - available on demand at www.IASLC.org) addressed the role of surgery for malignant mesothelioma and updated the status of systemic therapy of this disease. Despite advances in treatment, this disease remains a formidable challenge.
September 12, 2016 at 8:00PM EST; September 14, 2016 at 9:00PM EST; September 16, 2016 at 11:00PM EST - Recordings Available
This sixty-minute webinar will feature 3 presentations. The webinar is being presented at three different times and features the same three speakers.
August 16, 2016 at 9:00PM EDT - Recording Available
This live session of IASLC Lung Cancer Grand Rounds features Dr. Brett Carter. This presentation will discuss the role of advanced imaging techniques in evaluating lung cancer.
Wednesday July 27, 2016 9:00PM EDT - Recording Available
Malignant Pleural Mesothelioma (MPM) remains one of the most intractable malignancies with current overall survival (OS) of about 12 months in unresectable advanced stages. Multimodality therapy in resectable patients yields median OS of 17-25 months. Recently, the field has made several advances due to novel discoveries and initiatives in epidemiology, screening/detection and treatment.
July 7, 2016 6:00PM CEST - Recording Available
This program will review radiation therapy for lung cancer highlights from the recent 2016 annual meeting of the American Society of Clinical Oncology (ASCO). The focus of the presentations are upon the most relevant data and reports that impact current standards of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC).
July 5, 2016 at 6:00 PM CEST - Recording Available
Patients harboring EGFR mutations represent a subgroup of non-small cell lung cancer (NSCLC) with high sensitivity to EGFR-Tyrosine kinase inhibitors. Many agents are currently available in clinical practice with small differences in terms of efficacy and toxicity profile.